Online inquiry

IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2259MR)

This product GTTS-WQ2259MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets F gene. The antibody can be applied in Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Lama glama
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID P03420
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2259MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14559MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ5224MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ13562MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ362MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ8051MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ14457MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ3757MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ14248MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG-7116
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW